What is Leerink Partnrs’ Estimate for IONS FY2027 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities researchers at Leerink Partnrs increased their FY2027 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued to investors on Tuesday, September 2nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.42) for the year, up from their prior estimate of ($1.71). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at ($0.80) EPS.

Other research analysts have also recently issued reports about the company. Morgan Stanley upgraded Ionis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $55.00 to $62.00 in a research note on Thursday, July 31st. Jefferies Financial Group increased their price target on Ionis Pharmaceuticals from $83.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday. BMO Capital Markets upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $40.00 to $70.00 in a research note on Wednesday. Stifel Nicolaus set a $43.00 target price on Ionis Pharmaceuticals in a research report on Thursday, August 21st. Finally, Wall Street Zen raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $67.88.

Ionis Pharmaceuticals Stock Up 3.2%

Shares of IONS opened at $61.23 on Friday. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $62.08. The stock has a market capitalization of $9.76 billion, a price-to-earnings ratio of -33.28 and a beta of 0.28. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. The stock has a fifty day moving average of $43.65 and a 200-day moving average of $36.34.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.51. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The company had revenue of $452.00 million during the quarter, compared to analysts’ expectations of $270.90 million. During the same period in the prior year, the company earned ($0.45) EPS. Ionis Pharmaceuticals’s revenue was up 100.9% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP C Frank Bennett sold 33,909 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $60.62, for a total value of $2,055,563.58. Following the completion of the transaction, the executive vice president directly owned 101,570 shares of the company’s stock, valued at approximately $6,157,173.40. This trade represents a 25.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director B Lynne Parshall sold 20,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $50.91, for a total value of $1,018,200.00. Following the completion of the transaction, the director directly owned 66,344 shares of the company’s stock, valued at approximately $3,377,573.04. This trade represents a 23.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,141 shares of company stock worth $26,772,779. Corporate insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IONS. Allworth Financial LP raised its position in shares of Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after acquiring an additional 517 shares in the last quarter. Signaturefd LLC grew its stake in shares of Ionis Pharmaceuticals by 45.6% in the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after buying an additional 433 shares during the period. Ancora Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at about $60,000. Raiffeisen Bank International AG acquired a new stake in shares of Ionis Pharmaceuticals in the 4th quarter valued at about $62,000. Finally, CWM LLC grew its stake in shares of Ionis Pharmaceuticals by 18.7% in the 1st quarter. CWM LLC now owns 2,435 shares of the company’s stock valued at $73,000 after buying an additional 384 shares during the period. 93.86% of the stock is owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.